ElendiLabs Logo
Back to Articles

Need Regulatory Help? Try Our Platform

Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.

Registration

February 2, 2025

Approximately 5 minutes

Medical Device Registration in France: Compliance under the EU MDR and the ANSM

Medical Device Registration in France: Compliance under the EU MDR

Medical device registration and market access in France are primarily governed by the European Union’s legislative framework, specifically the Medical Device Regulation (EU MDR 2017/745) and the In Vitro Diagnostic Regulation (EU IVDR 2017/746).


1. The National Competent Authority (ANSM)

The national body responsible for overseeing the implementation and enforcement of the EU MDR/IVDR in France is the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM). While the registration process is centralized under the EU system, the ANSM is the national point of contact for manufacturers, importers, and distributors, handling market surveillance and vigilance reporting.


2. Mandatory Conformity Marking (CE Mark)

To be legally placed on the French market, a medical device must bear the CE Mark. Achieving the CE Mark requires:

  • Classification: Determining the device class (I, IIa, IIb, III or IVDs) based on risk.
  • Conformity Assessment: Low-risk devices (Class I non-sterile/non-measuring) can be self-certified. Higher-risk devices require assessment by an EU Notified Body to confirm compliance with the EU MDR’s General Safety and Performance Requirements (GSPRs).
  • Technical Documentation: Creation and maintenance of a comprehensive Technical File/Design Dossier.
  • Declaration of Conformity: The manufacturer’s written declaration that the device meets all regulatory requirements.

3. Registration Requirements

Under the EU MDR, registration is primarily conducted via the European Database on Medical Devices (EUDAMED).

  • Manufacturer/Authorized Representative (AR): Manufacturers (or their appointed EU Authorized Representative for non-EU manufacturers) must register themselves and their devices in EUDAMED.
  • Importer/Distributor: Importers and Distributors placing devices on the French market must also register their activities with the ANSM, ensuring full traceability of devices.
  • UDI: Devices require a Unique Device Identification (UDI) to be entered into EUDAMED for tracking purposes.

Ask Anything

We'll follow up with you personally.

100% response rate • Reply within 7 business days

Your email will not be published. We'll only use it to notify you when we respond.

Questions & Answers (5)

J
Guest

Our SaMD (Software as a Medical Device) is intended to interface with the French national health record system, Mon Espace Santé. Beyond the MDR Annex I requirements for cybersecurity, what are the 2026 specific French technical standards for interoperability and HDS (Hébergeur de Données de Santé) certification? Is a standard SOC2 or ISO 27001 report sufficient for ANSM and the Digital Health Agency (ANS)?

ElendiLabs

HDS Certification: For the French market, ISO 27001 is a prerequisite but not sufficient. Your cloud provider (and your own infrastructure, if you handle patient data) must hold a specific HDS certification (tiers 3 to 6 depending on the data type). • Interoperability: By 2026, all connected MDs in France must comply with the 'Doctrine Technique du Numérique en Santé'. You should obtain an interoperability certificate from GIE SESAM-Vitale to ensure your device can communicate with the French healthcare card system and the national health hub. Failure to demonstrate this 'French-specific' digital compliance might disqualify you from any public hospital tenders or state-funded reimbursement schemes.

J
Guest

We manufacture custom-made cranial implants which are now reclassified as Class III under MDR Article 52(8). With the May 26, 2026 deadline looming, we have already implemented a Quality Management System (QMS). If our Notified Body (NB) has not yet issued the final QMS certificate by this date, can we continue placing these devices on the French market under the 'Legacy Device' provision, or do we need a specific 'Derogation' from ANSM?

ElendiLabs

The May 2026 Hard Deadline: For Class III custom-made implantable devices, there is no automatic extension beyond May 26, 2026, unless you have a certified QMS in place. • Regulatory Action: If the NB audit is delayed, you must have applied for conformity assessment and signed a written agreement with an NB before the 2024 cutoff. By 2026, if the certificate is still pending, you may need to apply for a national derogation under MDR Article 59 from ANSM. This is granted only if there is a critical "patient need" or a shortage of specific implants in French hospitals. Without this, your devices will be considered non-compliant as of May 27, 2026.

A
Guest

我们的 III 类植入式心脏起搏器仅供法国大型医院的专科医生使用。考虑到欧盟 MDR 允许成员国自行决定语言要求,且医生通常具备英语能力,我们能否为了降低包装成本,在法国市场仅提供英文版 IFU(使用说明书)?如果不行,ANSM 对于电子说明书 (e-IFU) 的法语翻译是否有特定的法律免责条款?

ElendiLabs

法语语言法: 法国《图邦法》(Loi Toubon) 极其严格。即便该器械由专业人员使用,ANSM 依然要求标签和 IFU 必须提供法语版本。 • e-IFU 限制: 只有在符合 (EU) 2021/2226 法规(针对植入式、固定安装式器械等)的情况下,您才可以使用 e-IFU。但即使是电子版,其内容也必须包含法语。2026 年的审查中,若发现缺少法语说明,ANSM 有权直接开出高达 150,000 欧元的行政罚款,并要求产品下架。

A
Guest

我们研发的一款带有 AI 算法的微型监测器已获得 MDR 证书。我们希望进入法国公立医保报销名录 (LPPR)。在 2026 年,如果我们的产品具有显著的‘临床附加值 (ASA)’,能否申请 ‘Forfait Innovation’ 路径来获得早期的过渡期资金支持?这与正式的 CNEDiMTS 评审在时间线上如何配合?

ElendiLabs

创新路径: Forfait Innovation 是 2026 年法国政府大力推行的政策。如果您的 AI 监测器属于突破性技术,可以在尚未完成大规模临床获益验证前,通过该路径获得为期 2-3 年 的报销。 • 评审配合: 您需同时启动 HAS (法国高级健康局) 的 CNEDiMTS 评审。2026 年的新规要求厂商在获得“创新补偿”期间,必须同步在法国本地医院收集 RWE(真实世界证据),以作为最终进入 LPPR 正式名录的考核指标。

A
Guest

我们计划在 2026 年 6 月 首次向法国市场投放一款 IIa 类电子内窥镜。届时 EUDAMED 的前四个模块(参与者、UDI/器械、公告机构、市场监督)已正式转为强制性。如果我们尚未在 EUDAMED 获得 SRN(单一注册编号),仅持有现有的法国 ANSM 国家级报备编号,我们是否仍能合法清关进入马赛港?此时是否还需在法国本地系统进行双重注册?

ElendiLabs

2026 年 5 月 28 日后,SRN 是准入的“唯一身份证”。没有 SRN,您无法在 EUDAMED 上传 UDI 数据,海关也将因为无法在欧盟公共数据库查验器械信息而拒绝准入。 本地报备: 尽管 EUDAMED 已强制,法国 ANSM 仍保留了对进入法国市场的 II 类及以上器械的国家级告知义务 (Communication)。这意味着您需要在获得 SRN 的基础上,通过 ANSM 的本地平台提交产品的摘要信息。这种“双重报备”在 2026 年的过渡期内依然是合规要点。

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550